. 2021 Dec;2(12):1321-1337.

doi: 10.1038/s43018-021-00275-9. Epub 2021 Oct 27.

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Annika Fendler^#¹, Lewis Au^#^{1

2}, Scott T C Shepherd^#^{1

2}, Fiona Byrne¹, Maddalena Cerrone^{3

4}, Laura Amanda Boos², Karolina Rzeniewicz¹, William Gordon¹, Benjamin Shum^{1

2}, Camille L Gerard¹, Barry Ward¹, Wenyi Xie¹, Andreas M Schmitt², Nalinie Joharatnam-Hogan², Georgina H Cornish⁵, Martin Pule^{6

7}, Leila Mekkaoui⁷, Kevin W Ng⁵, Eleanor Carlyle², Kim Edmonds², Lyra Del Rosario², Sarah Sarker², Karla Lingard², Mary Mangwende², Lucy Holt², Hamid Ahmod², Richard Stone⁸, Camila Gomes⁸, Helen R Flynn⁹, Ana Agua-Doce¹⁰, Philip Hobson¹⁰, Simon Caidan¹¹, Michael Howell¹², Mary Wu¹², Robert Goldstone¹³, Margaret Crawford¹³, Laura Cubitt¹³, Harshil Patel¹⁴, Mike Gavrielides¹⁵, Emma Nye⁸, Ambrosius P Snijders⁹, James I MacRae¹⁶, Jerome Nicod¹³, Firza Gronthoud¹⁷, Robyn L Shea^{17

18}, Christina Messiou¹⁹, David Cunningham²⁰, Ian Chau²⁰, Naureen Starling²⁰, Nicholas Turner^{21

22}, Liam Welsh²³, Nicholas van As²⁴, Robin L Jones²⁵, Joanne Droney²⁶, Susana Banerjee²⁷, Kate C Tatham^{28

29}, Shaman Jhanji²⁸, Mary O'Brien³⁰, Olivia Curtis³⁰, Kevin Harrington^{31

32}, Shreerang Bhide^{31

32}, Jessica Bazin³³, Anna Robinson³³, Clemency Stephenson³³, Tim Slattery², Yasir Khan², Zayd Tippu², Isla Leslie², Spyridon Gennatas^{34

35}, Alicia Okines^{21

34}, Alison Reid³⁶, Kate Young², Andrew J S Furness², Lisa Pickering², Sonia Gandhi^{37

38}, Steve Gamblin³⁹, Charles Swanton^{40

41}; Crick COVID-19 Consortium; Emma Nicholson³³, Sacheen Kumar²⁰, Nadia Yousaf^{30

34}, Katalin A Wilkinson^{3

42}, Anthony Swerdlow⁴³, Ruth Harvey⁴⁴, George Kassiotis⁵, James Larkin², Robert J Wilkinson^{3

4

42}, Samra Turajlic^{45

46}; CAPTURE consortium

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
² Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ Tuberculosis Laboratory, The Francis Crick Institute, London, UK.
⁴ Department of Infectious Disease, Imperial College London, London, UK.
⁵ Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
⁶ Department of Haematology, University College London Cancer Institute, London, UK.
⁷ Autolus Ltd., London, UK.
⁸ Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
⁹ Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.
¹⁰ Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK.
¹¹ Safety, Health and Sustainability, The Francis Crick Institute, London, UK.
¹² High Throughput Screening Laboratory, The Francis Crick Institute, London, UK.
¹³ Advanced Sequencing Facility, The Francis Crick Institute, London, UK.
¹⁴ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁵ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, UK.
¹⁶ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, UK.
¹⁷ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁸ Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, UK.
¹⁹ Department of Radiology, The Royal Marsden NHS Foundation Trust, London, UK.
²⁰ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK.
²¹ Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²² Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
²³ Neuro-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁴ Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁵ Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
²⁶ Palliative Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
²⁷ Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁸ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.
²⁹ Department of Surgery and Cancer, Imperial College London, London, UK.
³⁰ Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK.
³¹ Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
³² Targeted Therapy Team, The Institute of Cancer Research, London, UK.
³³ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
³⁴ Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.
³⁵ Department of Medical Oncology, Guy's Hospital, London, UK.
³⁶ Uro-oncology Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK.
³⁷ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK.
³⁸ UCL Queen Square Institute of Neurology, London, UK.
³⁹ Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.
⁴⁰ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
⁴¹ University College London Cancer Institute, London, UK.
⁴² Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Cape Town, Republic of South Africa.
⁴³ Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
⁴⁴ Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
⁴⁵ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.
⁴⁶ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK. samra.turajlic@crick.ac.uk.

^# Contributed equally.

PMID: 35121900
DOI: 10.1038/s43018-021-00275-9

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Annika Fendler et al. Nat Cancer. 2021 Dec.

. 2021 Dec;2(12):1321-1337.

doi: 10.1038/s43018-021-00275-9. Epub 2021 Oct 27.

Authors

Affiliations

¹ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
² Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
³ Tuberculosis Laboratory, The Francis Crick Institute, London, UK.
⁴ Department of Infectious Disease, Imperial College London, London, UK.
⁵ Retroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
⁶ Department of Haematology, University College London Cancer Institute, London, UK.
⁷ Autolus Ltd., London, UK.
⁸ Experimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
⁹ Mass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.
¹⁰ Flow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK.
¹¹ Safety, Health and Sustainability, The Francis Crick Institute, London, UK.
¹² High Throughput Screening Laboratory, The Francis Crick Institute, London, UK.
¹³ Advanced Sequencing Facility, The Francis Crick Institute, London, UK.
¹⁴ Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.
¹⁵ Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, UK.
¹⁶ Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, UK.
¹⁷ Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
¹⁸ Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, UK.
¹⁹ Department of Radiology, The Royal Marsden NHS Foundation Trust, London, UK.
²⁰ Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK.
²¹ Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²² Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
²³ Neuro-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁴ Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁵ Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
²⁶ Palliative Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
²⁷ Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
²⁸ Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.
²⁹ Department of Surgery and Cancer, Imperial College London, London, UK.
³⁰ Lung Unit, The Royal Marsden NHS Foundation Trust, London, UK.
³¹ Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
³² Targeted Therapy Team, The Institute of Cancer Research, London, UK.
³³ Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
³⁴ Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.
³⁵ Department of Medical Oncology, Guy's Hospital, London, UK.
³⁶ Uro-oncology Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK.
³⁷ Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK.
³⁸ UCL Queen Square Institute of Neurology, London, UK.
³⁹ Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.
⁴⁰ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
⁴¹ University College London Cancer Institute, London, UK.
⁴² Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Cape Town, Republic of South Africa.
⁴³ Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
⁴⁴ Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
⁴⁵ Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.
⁴⁶ Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK. samra.turajlic@crick.ac.uk.

^# Contributed equally.

PMID: 35121900
DOI: 10.1038/s43018-021-00275-9

Abstract

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4⁺ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.

PubMed Disclaimer

Update of

Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler A, Au L, Shepherd STC, Byrne F, Cerrone M, Boos LA, Rzeniewicz K, Gordon W, Shum B, Gerard CL, Ward B, Xie W, Schmitt AM, Joharatnam-Hogan N, Cornish GH, Pule M, Mekkaoui L, Ng KW, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Stone R, Gomes C, Flynn HR, Agua-Doce A, Hobson P, Caidan S, Howell M, Wu M, Goldstone R, Crawford M, Cubitt L, Patel H, Gavrielides M, Nye E, Snijders AP, MacRae JI, Nicod J, Gronthoud F, Shea RL, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, Jhanji S, O'Brien M, Curtis O, Harrington K, Bhide S, Bazin J, Robinson A, Stephenson C, Slattery T, Khan Y, Tippu Z, Leslie I, Gennatas S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Gandhi S, Gamblin S, Swanton C, Nicholson E, Kumar S, Yousaf N, Wilkinson KA, Swerdlow A, Harvey R, Kassiotis G, Larkin J, Wilkinson RJ, Turajlic S. Fendler A, et al. Res Sq [Preprint]. 2021 Sep 20:rs.3.rs-916427. doi: 10.21203/rs.3.rs-916427/v1. Res Sq. 2021. Update in: Nat Cancer. 2021 Dec;2(12):1321-1337. doi: 10.1038/s43018-021-00275-9. PMID: 34580668 Free PMC article. Updated. Preprint.

Comment in

Capturing adaptive immunity against SARS-CoV-2 in patients with cancer.
Luxenburger H, Thimme R. Luxenburger H, et al. Nat Cancer. 2021 Dec;2(12):1298-1300. doi: 10.1038/s43018-021-00298-2. Nat Cancer. 2021. PMID: 35121915 No abstract available.

References

1. Saini, K. S. et al. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur. J. Cancer 139, 43–50 (2020). - PubMed - PMC - DOI
1. Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436 (2020). - PubMed - PMC - DOI
1. Garcia-Suarez, J. et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J. Hematol. Oncol. 13, 133 (2020). - PubMed - PMC - DOI
1. Garassino, M. C. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 21, 914–922 (2020). - PubMed - PMC - DOI
1. Lee, L. Y. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395, 1919–1926 (2020). - PubMed - PMC - DOI

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Supplementary concepts

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Affiliations

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Authors

Affiliations

Abstract

Update of

Comment in

References

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous